Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies.

Swaminathan S, Sangwai M, Wawdhane S, Vavia P.

AAPS PharmSciTech. 2013 Mar;14(1):360-74. doi: 10.1208/s12249-012-9918-9. Epub 2013 Jan 19.

2.

Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.

Mou D, Chen H, Wan J, Xu H, Yang X.

Int J Pharm. 2011 Jul 15;413(1-2):237-44. doi: 10.1016/j.ijpharm.2011.04.034. Epub 2011 Apr 21.

PMID:
21540090
3.

Formulation and in vivo human bioavailability of dissolving tablets containing a self-nanoemulsifying itraconazole solid dispersion without precipitation in simulated gastrointestinal fluid.

Piao ZZ, Choe JS, Oh KT, Rhee YS, Lee BJ.

Eur J Pharm Sci. 2014 Jan 23;51:67-74. doi: 10.1016/j.ejps.2013.08.037. Epub 2013 Sep 5.

PMID:
24012590
4.

Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.

Sun W, Ni R, Zhang X, Li LC, Mao S.

Drug Dev Ind Pharm. 2015 Jun;41(6):927-33. doi: 10.3109/03639045.2014.914528. Epub 2014 May 2.

PMID:
24785575
5.

Effect of decisive formulation variables on bioencapsulation efficiency and integrity of yeast biocapsules for oral itraconazole delivery.

Sangwai MB, Vavia PR.

J Microencapsul. 2011;28(4):311-22. doi: 10.3109/02652048.2011.569762.

PMID:
21545322
6.

Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles.

Yoo SD, Lee SH, Kang E, Jun H, Jung JY, Park JW, Lee KH.

Drug Dev Ind Pharm. 2000 Jan;26(1):27-34.

PMID:
10677807
7.

Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.

DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams RO 3rd.

Mol Pharm. 2008 Nov-Dec;5(6):968-80. doi: 10.1021/mp800042d.

PMID:
19434851
9.

Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.

Duret C, Merlos R, Wauthoz N, Sebti T, Vanderbist F, Amighi K.

Eur J Pharm Biopharm. 2014 Jan;86(1):46-54. doi: 10.1016/j.ejpb.2013.03.005. Epub 2013 Mar 21.

PMID:
23523546
10.

A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics.

Yi Y, Yoon HJ, Kim BO, Shim M, Kim SO, Hwang SJ, Seo MH.

J Control Release. 2007 Jan 22;117(1):59-67. Epub 2006 Oct 6.

PMID:
17097755
11.

Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: in vitro and in vivo studies.

Mutalik S, Manoj K, Reddy MS, Kushtagi P, Usha AN, Anju P, Ranjith AK, Udupa N.

AAPS PharmSciTech. 2008;9(2):651-9. doi: 10.1208/s12249-008-9075-3. Epub 2008 May 24.

12.

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.

Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodríguez P, Márquez S, Guarneri C, Estevez-Parrillo FT, Laurenz M, Estevez-Carrizo FE.

Clin Ther. 2009 Oct;31(10):2224-32. doi: 10.1016/j.clinthera.2009.10.009.

PMID:
19922893
13.

Preparation of rapidly disintegrating tablets containing itraconazole solid dispersions.

Oshima T, Sonoda R, Ohkuma M, Sunada H.

Chem Pharm Bull (Tokyo). 2007 Nov;55(11):1557-62.

14.

Development of stabilized itraconazole nanodispersions by using high-gravity technique.

Zhang ZL, Le Y, Wang JX, Zhao H, Chen JF.

Drug Dev Ind Pharm. 2012 Dec;38(12):1512-20. doi: 10.3109/03639045.2012.654794. Epub 2012 Mar 22.

PMID:
22435399
15.

Single dose and multiple dose studies of itraconazole nanoparticles.

Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, Williams RO 3rd.

Eur J Pharm Biopharm. 2006 Jun;63(2):95-102. Epub 2006 Mar 3.

PMID:
16516450
16.

Laponite-based nanohybrid for enhanced solubility and controlled release of itraconazole.

Jung H, Kim HM, Choy YB, Hwang SJ, Choy JH.

Int J Pharm. 2008 Feb 12;349(1-2):283-90. Epub 2007 Aug 17.

PMID:
17888597
17.

Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption.

Sun W, Mao S, Shi Y, Li LC, Fang L.

J Pharm Sci. 2011 Aug;100(8):3365-73. doi: 10.1002/jps.22587. Epub 2011 Apr 24.

PMID:
21520089
18.

Bioequivalence study of two formulations of 100 mg capsule of itraconazole. Quantification by tandem mass spectrometry.

Manfio JL, dos Santos MB, Favreto WA, Weich A, Pugens AM, Donaduzzi CM.

Arzneimittelforschung. 2010;60(3):157-61. doi: 10.1055/s-0031-1296265.

PMID:
20422948
19.

Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model.

McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS, Talbert RL, Peters JI, Johnston KP, Williams RO 3rd.

Pharm Res. 2006 May;23(5):901-11. Epub 2006 May 5.

PMID:
16715380
20.

Formulation and in vitro and in vivo evaluation of film-coated montelukast sodium tablets using Opadry® yellow 20A82938 on an industrial scale.

Zaid AN, Natour S, Qaddomi A, Abu Ghoush A.

Drug Des Devel Ther. 2013;7:83-91. doi: 10.2147/DDDT.S37369. Epub 2013 Feb 7.

Supplemental Content

Support Center